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Abstract
Background: Glycaemic control in women with diabetes is critical to satisfactory pregnancy outcome. A
systematic review of two randomised trials concluded that there was no clear evidence of benefit from
very tight versus tight glycaemic control for pregnant women with diabetes.
Methods: A systematic review of observational studies addressing miscarriage, congenital malformations
and perinatal mortality among pregnant women with type 1 and type 2 diabetes was carried out. Literature
searches were performed in MEDLINE, EMBASE, CINAHL and Cochrane Library. Observational studies
with data on glycated haemoglobin (HbA1c) levels categorised into poor and optimal control (as defined
by the study investigators) were selected. Relative risks and odds ratios were calculated for HbA1c and
pregnancy outcomes. Adjusted relative risk estimates per 1-percent decrease in HbA1c were calculated for
studies which contained information on mean and standard deviations of HbA1c.
Results: The review identified thirteen studies which compared poor versus optimal glycaemic control in
relation to maternal, fetal and neonatal outcomes. Twelve of these studies reported the outcome of
congenital malformations and showed an increased risk with poor glycaemic control, pooled odds ratio
3.44 (95%CI, 2.30 to 5.15). For four of the twelve studies, it was also possible to calculate a relative risk
reduction of congenital malformation for each 1-percent decrease in HbA1c, these varied from 0.39 to
0.59. The risk of miscarriage was reported in four studies and was associated with poor glycaemic control,
pooled odds ratio 3.23 (95%CI, 1.64 to 6.36). Increased perinatal mortality was also associated with poor
glycaemic control, pooled odds ratio 3.03 (95%CI, 1.87 to 4.92) from four studies.
Conclusion: This analysis quantifies the increase in adverse pregnancy outcomes in women with diabetes
who have poor glycaemic control. Relating percentage risk reduction in HbA1c to relative risk of adverse
pregnancy events may be useful in motivating women to achieve optimal control prior to conception.
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Background
Diabetes is the most common pre-existing medical condi-
tion complicating pregnancy in the United Kingdom
(approximately four occurrences per 1000 pregnancies)
[1]. It is known to have a substantial impact on maternal,
fetal and neonatal outcomes. The presence of diabetes is
said to increase the risk of congenital malformation (by
ten-fold), the risk of stillbirth (by five-fold), and the risk
of neonatal death (by three-fold) [2-7] These disappoint-
ing data are in contrast to the optimism of the 1989 St
Vincent's Declaration that proposed as a five year target
that the outcome of pregnancy should approximate that
of the non-diabetic pregnancy [8].
A pivotal part of management is good diabetic control
which is believed to reduce the incidence of pregnancy
complications. Glycated haemoglobin (HbA1c) reflects
long-term glycaemic control and is a more accurate and
stable measure than fasting blood glucose levels [9]. It
tracks well over time in individuals with diabetes and has
less variability than fasting blood glucose.
Longer term glycaemic control in women with diabetes is
critical to satisfactory pregnancy outcome. As organogen-
esis takes place in the first trimester of pregnancy, inade-
quate pre-conceptual glycaemic control is associated with
an increased risk of congenital abnormality and spontane-
ous abortion [10,11].
Clinical management decisions are limited by a dearth of
randomised trial data due to ethical reasons and current
practice must rely on the findings of high quality observa-
tional studies.
The objective of the study was to perform a systematic
review of observational studies to investigate and quantify
the risk of adverse pregnancy outcomes in pregnant
women with diabetes in relation to glycaemic control,
whether poor or optimal.
Methods
Study design
We systematically reviewed observational studies of gly-
cated haemoglobin and pregnancy outcomes in women
with diabetes mellitus.
Study selection
We searched the MEDLINE database for articles published
in English from 1966 to January 2005 by using Medical
Subject Heading terms and text words related to preg-
nancy, diabetes mellitus, glycaemic control and glycated
haemoglobin (Figure 1 contains the full text of the search
strategy). We also searched EMBASE, CINAHL and the
Cochrane Library.
We reviewed all abstracts obtained from our search for rel-
evance. We manually reviewed bibliographies and review
articles for additional citations and obtained the full text
of potentially relevant articles.
Our pre-specified inclusion criteria were as follows: 1)
published observational studies; 2) studies that examined
pregnancy outcomes in women with type 1 and type 2
diabetes; and 3) studies that reported a measure of gly-
cated haemoglobin and had clearly categorised pregnancy
outcomes according to poor and optimal glycaemic con-
trol using a cut-off point. Case-control studies were
included in the review only if there was clear distinction
between optimal and poor glycaemic control in relation
to outcomes in the cases (patients with diabetes). Control
data from case-control studies were not used in this
review. We excluded studies if they included women with
gestational diabetes.
Data abstraction
One investigator reviewed each article that met the selec-
tion criteria and abstracted the data by using standardised
data abstraction forms. Information was collected on
study design, country of study, time-period of study, gly-
caemic control groups, method of measuring glycated
haemoglobin, and timing of glycaemic control measure-
ment. Data abstracted were age, parity, smoking, duration
of diabetes, pre-pregnancy planning, folic acid consump-
tion, presence of microvascular complications, pre-preg-
nancy insulin dose, sample size, type of outcome or
outcomes, main results, statistical methods and variables,
if any, which were included in the adjusted model or
models.
For each study that met our inclusion criteria, we
abstracted relative risks and odds ratios for the association
between adverse pregnancy outcomes and poor vs. opti-
mal glycaemic control if they were stated. If not, then the
relative risks and odds ratios were calculated from infor-
mation stated in each study.
A range of outcomes were investigated, however due to
the quality of data we focussed on congenital malforma-
tions, miscarriage and perinatal mortality (including still-
births and neonatal deaths).
A quality of reporting of meta-analyses of randomised
controlled trials (QUOROM) checklist was carried out
[see Additional file 1]. Quality assessment was modified
to suit a meta-analysis of observational studies rather than
randomized controlled trials, examining patient selection,
data extraction methods, losses to follow up, and con-
founding.BMC Pregnancy and Childbirth 2006, 6:30 http://www.biomedcentral.com/1471-2393/6/30
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Statistical analysis
In the primary analysis, glycated haemoglobin (HbA1c)
was the principal 'exposure' of interest. HbA1c was catego-
rised into poor and optimal control. Dichotomous out-
comes are expressed as odds ratios and 95% confidence
intervals are calculated. A test of heterogeneity, Cochran's
Q-test, was performed for each outcome and if no hetero-
geneity was present, a fixed-effects meta-analysis was per-
formed. If heterogeneity was marked, random effects
models were performed.
For studies that reported the mean and SD of HbA1c we
estimated the effect of a 1-unit percent change in HbA1c,
assuming a normal distribution for HbA1c values. We cal-
culated the 25th and 75th percentiles and divided the log
relative risk by the difference of these 2 values to give an
estimate of the effect of a 1-percent change in HbA1c [12].
We did not pool data from individual studies for these
analyses as the measurement of HbA1c differed between
centres.
We assessed publication bias where possible by using the
Egger test [13] and funnel plots which graphically display
the magnitude of the effect estimate by the inverse vari-
ance of the study. Sensitivity analyses assessed the relative
influence of each study by omitting one study at a time to
assess the influence of the single study on the pooled esti-
mate.
Statistical analyses were conducted using StatsDirect [14]
and Stata Version 8 software.
Results
Search results
Our study identified 880 published studies from our
search strategy. We retrieved the text of 256 and reviewed
them to assess whether they provided information on
HbA1c  and adverse pregnancy outcome in pregnant
women with type 1 and type 2 diabetes. After we applied
all exclusion and inclusion criteria, thirteen studies which
compared poor vs. optimal glycaemic control in relation
to maternal, fetal and neonatal outcomes, were included
in this review, (Figure 2 contains the flow diagram of stud-
ies). Of these, eight were cohorts, two case-controls, one
cross-sectional and two historical reviews.
Qualitative summary
Seven studies specifically looked at only women with
Type 1 diabetes and the remaining six studies included
both Type 1 and Type 2. Table 1 summarises the charac-
teristics of all studies included in the analysis. Study pop-
ulations were from United States, United Kingdom,
Finland, France, Netherlands, Sweden and Poland. Sam-
ple sizes ranged from 83 to 2459 participants in the largest
study, with a total of 5480 women. Most studies involved
Search strategy Figure 1
Search strategy.
1. Epidemiologic studies/
2. Exp case control studies/
3. Exp cohort studies/
4. Case control.tw.
5. (cohort adj (study or studies)).tw.
6. Cohort analys$.tw.
7. (Follow up adj (study or studies)).tw.
8. (observational adj (study or studies)).tw.
9. Longitudinal.tw.
10. Retrospective.tw.
11. Cross sectional.tw.
12. Cross-sectional studies/
13. Or/1-12
14. Diabetes Mellitus/ or Diabetes Mellitus, Type I/
15. Pregnancy in Diabetics/
16. Pregnan$.tw.
17. Pregnancy outcome$/
18. Pregnancy complication$/
19. Infant, Newborn/
20. Fetus/
21. Foetus.mp.
22. Fetal.mp.
23. Foetal.mp.
24. Embryo.mp. and Fetal Development/
25. Newborn.mp.
26. New-born.mp.
27. Childbirth.mp.
28. Labour.mp.
29. Labor, Obstetric/
30. Delivery, Obstetric/
31. Pregnancy failure.mp.
32. Miscarriage.mp.
33. abortion, spontaneous/
34. Abortion.mp.
35. abortion, induced/
36. termination.mp.
37. stillbirth.mp.
38. perinatal mortality.mp.
39. infant mortality/
40. Abnormalities/
41. congenital abnormalit$.mp.
42. congenital malformatio$.mp.
43. congenital anomal$.mp.
44. Birth defec$.mp.
45. neonatal trauma.mp.
46. birth injur$.mp.
47. neonatal hypoglycaemia.mp.
48. fetal macrosomia/
49. fetal distress/
50. intensive care, neonatal/
51. antepart$.mp.
52. prenatal.mp.
53. antenatal.mp.
54. perinatal.mp.
55. postnatal.mp.
56. postpart$.mp.
57. obstetrics/
58. preeclamp$/
59. Hypertensi$/
60. Diabetic nephropath$/
61. Diabetic retinopath$/
62. Haemoglobin A, Glycated
63. Hemoglobin A, Glycated
64. Or/16-63
65. 14 and 64
66. 15 and 64
67. 13 and 65
68. 13 and 66
69. 67 and 68BMC Pregnancy and Childbirth 2006, 6:30 http://www.biomedcentral.com/1471-2393/6/30
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Flow of studies in the review Figure 2
Flow of studies in the review.
Potentially appropriate studies to be 
included in the meta-analysis (n=37)
Studies included in meta-analysis 
(n=13)
Potentially relevant articles identified 
and screened for retrieval (n=880)
Studies excluded following
review of abstract (n=624)
Studies retrieved for more detailed
evaluation (n=256)
Studies excluded: (n=219)
Reasons: No categorisation of glycaemic control; 
Study population includes gestational diabetics;
Study carried out on diabetic population with 
substantial diabetic complications thus not 
representative of general diabetic population;
Patients on intensive insulin treatment; No relevant 
outcomes; Patients involved in trial; Review.
Studies excluded from the meta-analysis 
(n=25) 
Reasons: Glycaemic control groupings not 
related t o outcomes; Measurement of 
glycaemic control not based on glycated  
haemoglobin. 
Studies with usable information by 
outcomes (n=13)
Studies withdrawn, by outcome (n=0)BMC Pregnancy and Childbirth 2006, 6:30 http://www.biomedcentral.com/1471-2393/6/30
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patients who were receiving pregnancy care at the study
outpatient clinics. All studies described basic inclusion
and exclusion criteria for study participants.
The method of measurement of HbA1c varied across all the
studies. Five studies used high-performance liquid chro-
matography [7,15-18]. Other methods used included
spectrophotometric absorption, [19] column chromatog-
raphy, [20] cation exchange method, [21] thiobarbituric
acid colorimetric assay, [22] electrophoresis, [23] and iso-
electric focusing [24]. Two of the studies did not give
details on their method of measuring HbA1c [25,26].
All studies used different cut-off points for grouping
HbA1c into poor and optimal groups, varying from 5.6%
to 10.1%. The timing of the glycaemic control measure-
ment varied across the studies, the majority of studies
(twelve) measured HbA1c during the first trimester. One
study based glycaemic control on measurements taken at
the first antenatal visit, 20th and 28th week of gestation,
and just before delivery [26].
The data extraction method varied across the studies and
very few studies [15,17]. adjusted for potential confound-
ing factors in their analysis, (Table 2). Of these, neither
stated what specific factors they adjusted for in the analy-
sis.
Quantitative summary
The most common pregnancy outcome to be investigated
was the outcome of congenital malformation, in which
twelve out of the thirteen studies reported, (Table 3).
Spontaneous abortions and perinatal mortality were
reported in four of the studies, while all other maternal,
fetal and neonatal outcomes in Table 3 were reported in
only one of the studies.
The pooled estimate for patients with poor control and
the outcome of congenital malformations was 3.44 (95%
CI, 2.30 to 5.15), (Figure 3). Six studies only reported
major congenital malformations and the pooled estimate
was 5.14 (95% CI, 2.94 to 9.01), (Figure 4). It was possi-
ble to calculate a relative risk for each 1-percent point
increase in HbA1c for four out of the twelve studies which
investigated the outcome of congenital malformations,
these are presented in Table 4. The relative risk estimates
varied from 1.63 to 2.34 per 1-percent point increase in
HbA1c. These could be translated to a relative risk reduc-
tion per 1-percent point decrease in HbA1c and varied
from 0.39 to 0.59.
The pooled estimate for the outcome of miscarriage was
3.23 (95% CI, 1.64 to 6.36), (Figure 5) and for the out-
come of perinatal mortality an odds ratio of 3.03 (95% CI,
1.87 to 4.92), (Figure 6).
Sensitivity analyses indicated that three of the studies
seemed to contribute more greatly to the analysis
[15,16,25]. Sensitivity analyses, excluding the study with
the largest number of participants [25], produced similar
results.
Publication bias
A bias assessment plot for the outcome of congenital mal-
formations is shown in Figure 7. The Egger test was not
significant (P  > 0.05) for the congenital malformation
subgroup analysis. For the other outcomes however, the
small number of studies limits our ability to draw conclu-
sions regarding publication bias and heterogeneity of
studies.
Discussion
In our analysis of thirteen published studies, adverse preg-
nancy outcomes were associated with higher levels of
HbA1c in women with type 1 and type 2 diabetes mellitus.
These associations were present across different geo-
graphic populations and different time periods. A
decrease in HbA1c was associated with a clinically impor-
tant reduction in the risk of fetal congenital malforma-
tions.
The outcome of congenital malformations was the most
commonly reported outcome across the studies. Reasons
for this may be because many clinical and epidemiologi-
cal studies indicate that fetal malformations in pregnancy
complicated by diabetes are due to metabolic distur-
bances affecting the process of organogenesis, which takes
place at the early stage of pregnancy. The most common
malformations in infants of mothers with diabetes are
defects of the cardiovascular system. Studies suggest that
these tissues are the most susceptible ones to the destruc-
tive action of oxygen-free radicals [20]. Our analysis
shows that poor glycaemic control is associated with a
greater than three-fold risk for the outcome of congenital
malformations compared to optimal glycaemic control.
The rates of miscarriage and perinatal mortality were
higher in the poor glycaemic control groups compared
with the optimal control groups. Perinatal mortality rates
have markedly decreased over the last 25 years, however
there still appears to be a higher rate of perinatal mortality
with poorer levels of glycaemic control.
There are limited randomised trial data on the impact of
different levels of glycaemic control on outcome in dia-
betic pregnancies [27]. The randomised, prospective Dia-
betes Control and Complications Trial (DCCT) has
shown that timely institution of intensive therapy for
blood glucose control is associated with rates of spontane-
ous abortion and congenital malformations that are sim-
ilar to those in the non-diabetic populations [28]. A
Cochrane systematic review of randomised trials compar-B
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Table 1: Design characteristics of observational studies of glycated haemoglobin and pregnancy outcomes.
Author Country Study Design Time Period Sample size 
(n)
Glycaemic Control Groupings 
(n) (HbA1c unless stated)
Timing of Glycaemic 
Control Measurement
Outcomes (n)
Vaarasmaki et al, 2000 [26] Finland Cohort 1986–1995 84 Optimal < 8.0% (n = 48)
Poor > 8.0% (n = 36)
First antenatal visit 20 and 
28th week Before delivery
Malformations (n = 4)
Caesarean section (n = 34)
Stillbirth (n = 1)
NICU (n = 39)
Neonatal hypoglycaemia(n = 11)
RDS (n = 5)
Greene et al, 1989 [23] US Cohort Dec.5th 1983–Dec.31st 1987 303 Optimal ≤ 9.3% (n = 113)
Poor ≥ 9.4% (n = 190)
(Data based on HbA1)
1st trimester Malformations (n = 20)
Spontaneous abortion (n = 52)
Evers et al, 2004 [16] Netherlands Cohort April 1st 1999 – April 1st 2000 261 Optimal ≤ 7.0% (n = 212)
Poor ≥ 7.0% (n = 71)
1st trimester Malformations (n = 29)
Key et al, 1987 [19]. US Cohort Jan.1st 1979 – Dec.31st 1984 83 Optimal <7.5% (n = 8)
Poor ≥ 7.5% (n = 75)
1st trimester Malformations (n = 9)
Spontaneous abortion (n = 22)
Temple et al, 2002 [7] UK Cohort Jan. 1991–Dec. 2000 158 Optimal < 7.5% (n = 110)
Poor ≥ 7.5% (n = 48)
1st trimester booking Malformations (n = 5)
Stillbirth (n = 2)
Spontaneous abortion (n = 11)
Neonatal death (n = 2)
Kitzmiller et al, 1991 [22] USA Cohort 1982–1988 194 Optimal ≤ 7.6% (n = 53)
Poor > 7.6% (n = 141)
1st trimester booking visit Malformations (n = 13)
Ylinen et al, 1984 [21] Finland Cohort April 1978–Dec. 1982 142 Optimal ≤ 7.9% (n = 63)
Poor >7.9% (n = 79)
Before 16 weeks gestation Malformations (n = 17)
CEMACH, 2005 [25] England, Wales & 
Northern Ireland
Descriptive 
Cohort
March 1st 2002–Feb 28th 2003 2459 Optimal < 7% (n = 962)
Poor ≥ 7% (n = 1497)
1st trimester Malformations (n = 101)
Stillbirths or neonatal deaths (n = 67)
Hiilesmaa et al, 2000 [17] Finland Case-Control 1988 – 1997 587 Optimal ≤ 6.8% (n = 195)
Poor > 6.8% (n = 392)
Early pregnancy Pre-eclampsia (n = 77)
PIH (n = 65)
Hanson et al, 1990 [24] Sweden Case-Control 1982–1985 532 Optimal < 10.1% (n = 490)
Poor ≥ 10.1% (n = 42)
1st trimester Spontaneous abortion (n = 41)
Malformation (n = 21)
Diabetes and Pregnancy Group, France 
2003 [15]
France Cross-sectional Jan. 2000 – Dec. 2001 435 Optimal < 8.0% (n = 315)
Poor > 8.0% (n = 120)
1st trimester Malformations (n = 18)
Perinatal mortality (n = 19)
Preterm delivery (n = 147)
Miller et al, 1981 [18] US Case-series April 1977 – April 1980 116 Optimal ≤ 8.5% (n = 58)
Poor ≥ 8.6% (n = 58)
Initial value Malformations (n = 15)
Wender-Ozegowska et al, 2005 [20] Poland Case-Series 1st Jan. 1994–31st Jan. 1999 126 Optimal ≤ 5.6% (n = 43)
Poor > 5.6% (n = 83)
1st trimester Malformations (n = 14)BMC Pregnancy and Childbirth 2006, 6:30 http://www.biomedcentral.com/1471-2393/6/30
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ing very tight with tight control of diabetes in pregnancy
focused on two trials involving a total of 182 women. The
conclusion was that there was no clear evidence of benefit
from very tight versus tight glycaemic control for pregnant
women with diabetes [27]. Observational studies show
much less favourable outcomes in unselected popula-
tions. In many studies, adverse outcomes remain more
common among the infants of mothers with type 1 diabe-
tes than in the general population [8,29]. The targets of
the St. Vincent's Declaration of 1989 appear not to have
been met, thus far. Reasons for persistently poor out-
comes in these populations may include unplanned preg-
nancies, pregnancies in women who have not received
pre-conceptual care, or pregnancies in women who fail to
achieve optimal control despite adequate pre-conceptual
care.
The factors that influence women to seek preconception
care and counselling and then to actually achieve optimal
glycaemic control prior to conception have become
important to clinicians. Factors that seem to promote pre-
conception care include higher educational levels, higher
incomes, regular employment, and receiving encourage-
ment from their health care providers to avoid unplanned
pregnancies [30]. Past pregnancy experience may also play
a role through influencing behaviour concerning diabetic
control and health habits [31].
A systematic review of 14 cohort studies has shown that
pre-conception care aiming to achieve tight glycaemic
control is associated with a reduction in the rate of major
congenital abnormalities – 2.1% in the preconception
care recipients versus 6.5% in non recipients, relative risk
0.36, 95% CI 0.22 to 0.59 [32].
Patients who frequently monitor and adjust their diabetes
regimen are more likely to maintain strict control of their
blood glucose levels throughout pregnancy [33]. Our
Table 2: Quality assessment of included studies.
A u t h o r s  R e f e r e n c e 2 62 31 61 972 22 12 51 72 41 51 82 0
I s  t h e  h y p o t h e s i s  c l e a r l y  d e f i n e d YYYY Y YYYYYYYY
I n c l u s i o n  c r i t e r i a  d e f i n e d YYYY N YYYYYYYY
M e t h o d  o f  s a m p l e  s e l e c t i o n  s t a t e d YYYY Y YYYYYYYY
D a t a  e x t r a c t i o n  m e t h o d  s t a t e d YYYY N YYYYYYYY
A d e q u a t e  d e s c r i p t i o n  o f  d i a g n o s t i c  c r i t e r i a YYYY N YYYYYYNY
Clinical and demographic characteristics fully defined Y Y Y Y Y YYYYYYYY
C o m p l e t e  a n d  r e p r e s e n t a t i v e  s a m p l e  o f  p a t i e n t s YYYY Y YYYYYYYY
A p p r o p r i a t e  f o l l o w - u p  o f  p a t i e n t s YYYY Y YYYYYYYY
Losses to follow up N Y Y Y N Y NA N NA Y NA NA NA
U n b i a s e d  o u t c o m e YYYY Y YYYYYYYY
Fully defined outcome Y Y Y N N YYYYYYYN
A p p r o p r i a t e  o u t c o m e YYYY Y YYYYYYYY
O u t c o m e  k n o w n  f o r  a l l  o r  a  h i g h  p r o p o r t i o n  o f  p a t i e n t s YYYY Y YYYYYYYY
Fully defined prognostic variable Y Y Y Y Y YYYYYYYY
Prognostic variable available for all or a high proportion of 
patients
NY Y YYY Y N Y Y Y Y Y
C o n t i n u o u s  p r e d i c t o r  v a r i a b l e  a n a l y s e d  a p p r o p r i a t e l y YYYY Y YYYYYYYY
Statistical adjustment for all important prognostic variables N N N N N N N NA Y N Y N N
Table 3: Pregnancy outcomes and number of studies included in review reporting outcome.
Outcome No. of studies reporting outcomes
Congenital malformations 12
Spontaneous abortions 4
Perinatal mortality 4
Neonatal deaths 1
Preterm delivery 1
Neonatal hypoglycaemia 1
Neonatal Intensive Care Unit Admission 1
Respiratory Distress Syndrome 1
Caesarean Section 1
Pre-eclampsia 1
Pregnancy-induced hypertension 1BMC Pregnancy and Childbirth 2006, 6:30 http://www.biomedcentral.com/1471-2393/6/30
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findings support this with a marked increase in congenital
malformation in association with poor glycaemic control.
A decremental approach to HbA1c may appeal to women
who are overwhelmed at the prospect of achieving a dra-
matic change in control from poor to optimal. Advising
women that there is a potential health gain with each 1%
reduction may be a useful motivator in gradual reduction
to an optimal level or may provide some reassurance for
women who manage a large improvement but do not
quite achieve optimal levels.
This review has several limitations. It is unclear to what
extent methodologic limitations, such as residual con-
founding and selection bias, might exist in these studies.
The pooled odds ratios have been used to quantify the
risks, however the small number of studies meant that sta-
tistical analyses for heterogeneity and publication bias
were limited. Although the funnel plot for the outcome of
congenital malformation shows an indication of asymme-
try, with just twelve studies the power to detect asymmetry
in a funnel plot is low. Thus, we cannot make any conclu-
sions about publication bias and we cannot exclude the
possibility that the observed association is a result of pub-
lication bias. We believe our process of literature identifi-
cation was comprehensive and captured all of the
published studies on the relation between HbA1c and out-
comes in pregnant women with diabetes.
The studies use different definitions of poor and optimal
control, ranging from 5.6% to 10.1%. Reasons for this
include the use of different methods of measurements for
HbA1c and varying reference ranges for the non-diabetic
population. Nonetheless, the cut-offs used were appropri-
ate to the method used to measure HbA1c and relevant to
Risk of congenital malformation for poor versus optimal glycaemic control Figure 3
Risk of congenital malformation for poor versus optimal glycaemic control. Pooled odds ratio = 3.44 (95% CI = 
3.00 to 5.15). Chi2 (test odds ratio differs from 1) = 36.2 (df = 1) P < 0.001.
Odds ratio meta-analysis plot [random effects]
0.1 0.2 0.5 1 2 5 10 100 1000
Hanson 10.86 (3.72, 30.18)
CEMACH 1.90 (1.19, 3.11)
Wender-Ozegowska 2.04 (0.50, 11.97)
Miller 6.77 (0.56, 299.00)
DPG 3.49 (1.20, 10.42)
Kitzmiller 3.83 (1.05, 14.24)
Ylinen 4.31 (1.11, 24.30)
Temple 9.91 (0.93, 492.32)
Key 3.07 (0.14, 67.26)
Evers 2.05 (0.74, 5.37)
Greene 4.06 (1.12, 22.12)
Vaarasmaki 11.88 (0.69, infinity)
combined [random] 3.44 (2.30, 5.15)
odds ratio (95% confidence interval)BMC Pregnancy and Childbirth 2006, 6:30 http://www.biomedcentral.com/1471-2393/6/30
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the reference range in use for the individual study popula-
tions. For this reason it would have been inappropriate to
do a subgroup analysis using different cut-off levels as cat-
egories.
Definitions for several of the outcomes varied across the
studies, for example, the outcome of congenital malfor-
mations included both major and minor malformations
in some studies [16,26] while in others only included
major malformations [7,18].
Few studies adjusted for confounding factors in their anal-
ysis and there is no certainty that the observed association
was caused exclusively by an elevated HbA1c level rather
than to some degree by related confounders. In the major-
ity of the studies we do not know how advanced the
patients' diabetes was. Diabetic nephropathy and retinop-
Table 4: Relative risk estimates per 1-percentage point increase in glycated haemoglobin and the outcome of congenital 
malformation.
Author Mean SD 25th percentile 75th percentile Difference between 
25th and 75th 
percentile
Inverse 
Relative 
Risk
Relative Risk per 
1% point increase
Relative Risk per 
1% point decrease
Miller [18] 8.54 1.54 7.50 9.58 2.08 1.87 2.34 0.59
Greene [23] 10.10 1.99 8.76 11.44 2.68 1.31 1.63 0.39
Evers [16] 6.5 0.70 6.03 6.97 0.94 0.65 1.99 0.50
Key [19] 10.99 1.10 10.25 11.73 1.48 1.0 1.95 0.49
Risk of major congenital malformation for poor versus optimal glycaemic control Figure 4
Risk of major congenital malformation for poor versus optimal glycaemic control. Pooled odds ratio = 5.14 (95% 
CI = 3.00 to 9.01). Chi2 (test odds ratio differs from 1) = 32.8 (df = 1) P < 0.001.BMC Pregnancy and Childbirth 2006, 6:30 http://www.biomedcentral.com/1471-2393/6/30
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Risk of miscarriage for poor versus optimal glycaemic control Figure 5
Risk of miscarriage for poor versus optimal glycaemic control. Pooled odds ratio = 3.23 (95% CI = 1.64 to 6.36). Chi2 
(test odds ratio differs from 1) = 11.48 (df = 1) P = 0.001.
Odds ratio meta-analysis plot [random effects]
0.2 0.5 1 2 5 10 100 1000
Hanson 5.44 (2.23, 12.45)
Key 2.91 (0.34, 136.82)
Greene 1.77 (0.88, 3.72)
Temple 4.52 (1.07, 21.98)
combined [random] 3.23 (1.64, 6.36)
odds ratio (95% confidence interval)
Risk of perinatal mortality for poor versus optimal glycaemic control Figure 6
Risk of perinatal mortality for poor versus optimal glycaemic control. Pooled odds ratio = 3.03 (95% CI = 1.87 to 
4.92). Chi2 (test odds ratio differs from 1) = 20.13 (df = 1) P < 0.0001.
Odds ratio meta-analysis plot [random effects]
0.1 0.2 0.5 1 2 5 10 100 1000
CEMACH 2.73 (1.46, 5.49)
Temple 2.35 (0.16, 33.10)
Vaarasmaki 4.27 (0.32, 228.97)
DPG 3.87 (1.37, 11.36)
combined [random] 3.03 (1.87, 4.92)
odds ratio (95% confidence interval)BMC Pregnancy and Childbirth 2006, 6:30 http://www.biomedcentral.com/1471-2393/6/30
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athy are the most frequent complications in patients of
childbearing age with diabetes and will have an important
impact on pregnancy outcome [34]. One possible causal
factor for adverse outcome could be women with estab-
lished diabetes complications, such as microvascular dis-
ease. A single unsatisfactory HbA1c value cannot be used as
an absolute predictor of fetal outcome, but it indicates a
subgroup of pregnancies with substantial fetal risk [26].
Major advantages of pooling data from observational
studies to investigate this important clinical issue are bet-
ter generalisability because the analyses combine data
from heterogeneous populations, and increased sample
size.
Conclusion
Our systematic review highlights important weaknesses in
the literature. Studies to date are based on very small
numbers and this systematic review allows more robust
estimate of risk. Many important clinical outcomes were
not examined in the thirteen studies included in the
review. More than a decade after the initial evidence pro-
posing that pregnancy outcome was improved by better
glycaemic control, the question of how strict that control
should be remains unanswered. There remains an urgent
need to address the maternal and perinatal benefits of var-
ying degrees of control of blood sugar for pregnant
women with diabetes. Outcome measures should be
standardised and include important factors associated
with poor perinatal and maternal outcomes, such as pre-
eclampsia, macrosomia, caesarean section, shoulder dys-
tocia, perinatal loss, neonatal respiratory and metabolic
complications [27]. Future studies also need to investigate
the issue of pre-conceptual glycaemic control and post
pregnancy outcomes for the mother. We are currently
undertaking a study exploring the related issues of pre-
Bias assessment plot for the outcome of congenital malformations Figure 7
Bias assessment plot for the outcome of congenital malformations. Begg-Mazumdar: Kendall's tau = 0.33 P = 0.15. 
Egger: bias = 1.27 (95% CI = -0.01 to 2.56) P = 0.05. Horbold-Egger: bias = 2.19 (95% CI = 0.53 to 3.84) P = 0.03.
Bias assessment plot
-3.0 -0.5 2.0 4.5
1.6
1.2
0.8
0.4
0.0
Log(Odds ratio)
Standard errorBMC Pregnancy and Childbirth 2006, 6:30 http://www.biomedcentral.com/1471-2393/6/30
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conceptual glycaemic control, antenatal care, and mode of
delivery in terms of pregnancy-related, maternal and neo-
natal outcomes both in the short- and long-term.
We conclude that adverse pregnancy outcomes in women
with type 1 and type 2 diabetes mellitus were associated
with higher levels of HbA1c. This review summarises the
currently available evidence and should be useful to clini-
cians who are counselling women with type 1 and type 2
diabetes in the reproductive years.
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